TGTXTG THERAPEUTICS, INC.
Pharmaceutical Preparations
- Revenue
- $616M
- 87% YoY
- Operating margin
- 20.0%
- 57% YoY
- EBITDA
- $123M
- 194% YoY
- Market cap
- $9.4B
- Employees
- 399
- $2M revenue each
- Net debt / EBITDA
- -3.1×
- −$382M net debt
- AI in 10-K
- 3.0
- mentions per 10K words
Takeover score 6 of 13
Fixable underperformance 5 of 7
- TSR below peersYes5 of 5 years3+ of last 5 years
- High CEO pay despite TSRYes$19M medianMedian CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashYes-6% of net incomeCash flow under 80% of net income
- Dilutive SBCYes10% of revenueOver 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo0% of assetsOver 40% of assets
- Shareholder dissentYes40% lowest supportAny vote under 80% support
Buyer economics 1 of 4
- Low revenue per employeeNo$2M · 86th pctBottom quartile of its SIC industry
- Quiet on AINo3.0 per 10K words · 70th pctBottom quartile of AI mentions in 10-Ks
- Net cashYesNet cash · 3.1× EBITDAMore cash than debt, positive EBITDA
- Buyout-sizedNo$9.4B market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo−$438K netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $7M | $3M | $234M | $329M | $616M | 87% |
| Operating income | −$345M | −$218M | $21M | $42M | $123M | 194% |
| Net income | −$348M | −$198M | $13M | $23M | $447M | 1811% |
| Operating cash flow | −$296M | −$176M | −$31M | −$41M | −$25M | 39% |
| Capex | $401K | $14K | $0 | $45K | $214K | 376% |
| Stock-based comp | $61M | $45M | $38M | $43M | $65M | 52% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $438K · 2
- Net
- −$438K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $26M | $28M | 57 | 120 |
| FY2024 | $19M | $92M | 58 | 91 |
| FY2023 | $18M | $41M | 33 | 92 |
| FY2022 | $10M | −$43M | 23 | 89 |
| FY2021 | $43M | −$114M | 37 | 99 |